DFTX Q3 2025 Earnings — Definium Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DFTXDefinium Therapeutics, Inc.

$2B

Q3 2025 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$46M

Net Income

-$67M

EPS (Diluted)

$-0.78

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$30M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$237M

Total Liabilities

$106M

Stockholders' Equity

$131M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$46M	-$25M	-84.2%
Net Income	-$67M	-$14M	-391.6%